Adjuvance Technologies Inc.
CAGE Code: 5NFJ7
NCAGE Code: 5NFJ7
Status: Active
Type: Manufacturer
Dun & Bradstreet (DUNS): 831676247
Summary
Adjuvance Technologies Inc. is an Active Manufacturer with the Cage Code 5NFJ7 and is tracked by Dun & Bradstreet under DUNS Number 831676247..
Address
1225 L St Ste 600
Lincoln NE 68508-2139
United States
Points of Contact
- Telephone:
- 8165002933
- Fax:
- 6468670167
Related Information
People who viewed this 'CAGE Code' also viewed...
Brester Construction Inc State Fire Marshal Nebraska Lincoln Industries, Inc. Best Partition Corp Continental Power Services Co Conexsys, Llc Nebraska Radio Telephone Systems Inc The Arsenal Inc. And J.P.K Rbj Enterprises Vocational Foundation Of Nebraska Kriz-Davis Co Pratt Audio Visual & Video Corp Manpower Intl Inc Branchpattern Inc Visco Inc Stoll Andrew Shade Inc D. L. Thurrott, Inc. Donna Zimmerman Odgaard Consulting
Frequently Asked Questions (FAQ) for CAGE 5NFJ7
- What is CAGE Code 5NFJ7?
- 5NFJ7 is the unique identifier used by NATO Organizations to reference the physical entity known as Adjuvance Technologies Inc. located at 1225 L St Ste 600, Lincoln NE 68508-2139, United States.
- Who is CAGE Code 5NFJ7?
- 5NFJ7 refers to Adjuvance Technologies Inc. located at 1225 L St Ste 600, Lincoln NE 68508-2139, United States.
- Where is CAGE Code 5NFJ7 Located?
- CAGE Code 5NFJ7 is located in Lincoln, NE, USA.
Contracting History for CAGE 5NFJ7 Most Recent 25 Records
- 75N93019C00016
- Igf::Ot::Igf Preclinical Development Of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 In The Context Of An Influenza Vaccine. New Award
- 12 Jun 2019
- Igf::Ot::Igf Preclinical Development Of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 In The Context Of An Influenza Vaccine. New Award
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,471,319.00
- Department Of Health And Human Services (Hhs)
- HHSN272201700066C
- Igf::Ot::Igf Determining The Impact Of Semisynthetic Saponin Immunologic Adjuvant Titerquil-1055 On Influenza Vaccine Immunogenicity And Stability
- 31 Jul 2017
- Igf::Ot::Igf Determining The Impact Of Semisynthetic Saponin Immunologic Adjuvant Titerquil-1055 On Influenza Vaccine Immunogenicity And Stability
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $223,002.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00016
- Preclinical Development Of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 In The Context Of An Influenza Vaccine.
- 12 May 2020
- Preclinical Development Of Semisynthetic Saponin Immunological Adjuvant Titerquil-1055 In The Context Of An Influenza Vaccine.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,471,319.00
- Department Of Health And Human Services (Hhs)
- 75N93019C00016
- Incorporate The Change Order And Provided Funds In The Amount Of $899,905.
- 2 Aug 2019
- Incorporate The Change Order And Provided Funds In The Amount Of $899,905.
- National Institutes Of Health Niaid
- Department Of Health And Human Services (Hhs)
- $1,471,319.00
- Department Of Health And Human Services (Hhs)